No Interaction Expected
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP)
Quality of Evidence:
Coadministration with a gestodene-containing combined oral contraceptive (COC) has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Gestodene is metabolized by CYP3A4 and to a lesser extent by CYP2C9 and CYP2C19. Ethinylestradiol is mainly metabolized by hydroxylation. Emtricitabine/tenofovir-DF does not interact with these metabolic pathways. No clinically significant drug interactions were observed when tenofovir-DF was coadministered with a COC containing ethinylestradiol/norgestimate.
Coadministration of norgestimate/ethinylestradiol was studied with tenofovir disoproxil fumarate. Norgestimate AUC and Cmax decreased by 4% and 5%; ethinyl oestradiol AUC, Cmax and Cmin decreased by 4%, 6% and 2%, respectively. No dose adjustment of norgestimate/ethinyl estradiol is required.
Truvada Summary of Product Characteristics Gilead Sciences Ltd, June 2018.
No clinically significant drug interactions have been observed between TDF and oral contraceptives.
Truvada US Prescribing Information, Gilead Sciences Inc, May 2018.
View all available interactions with
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP) by clicking